Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of CC-99677 on Oral Contraceptive Pharmacokinetics
NCT04718636Phase 1Completed
- Sponsor
- Celgene Corporation
- Start
- Sep 2020
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of gamcemetinib in ankylosing spondylitis (AS), sponsored by Celgene Corporation. Primary endpoints: Area under the concentration-time curve from time zero to tau, Area under the concentration-time curve from time zero to the last quantifiable concentration and 5 more. Started Sep 2020; status: completed.
02
Drugs
gamcemetinib
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NCT04718636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04718636.